A Phase I Trial of HS-10241 in Solid Tumors
NCT02759640 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2022-07-20
Summary
This is a phase 1, open-label, dose-escalation trial of HS-10241 as monotherapy in subjects with solid tumors. HS-10241 will be administered orally once daily.
Conditions
Interventions
- DRUG
-
HS-10241
HS-10241 is administered orally starting at 100 mg/day.
Sponsors & Collaborators
-
Atridia Pty Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-09-30
- Primary Completion
- 2018-03-31
- Completion
- 2018-05-31
Countries
- Australia
Study Locations
More Related Trials
-
A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
NCT04324814 ·Status: COMPLETED ·Phase: PHASE1
-
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
NCT04746612 ·Status: TERMINATED ·Phase: PHASE1
-
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
NCT02492789 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
NCT03261011 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
NCT05593094 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
NCT06770569 ·Status: RECRUITING ·Phase: PHASE1
-
A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors
NCT00817518 ·Status: COMPLETED ·Phase: PHASE1
-
HW071021 Monotherapy in Patients With Advanced Solid Tumors
NCT06882135 ·Status: RECRUITING ·Phase: PHASE1
-
Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors
NCT02688101 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
NCT03352531 ·Status: COMPLETED ·Phase: PHASE1
-
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
NCT01760525 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114
NCT05200273 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
NCT04972981 ·Status: COMPLETED ·Phase: PHASE1
-
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
NCT06921837 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
NCT02517398 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
NCT04052971 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)
NCT00104364 ·Status: COMPLETED ·Phase: PHASE1
-
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
NCT01014936 ·Status: COMPLETED ·Phase: PHASE1
-
A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia
NCT01462175 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of HS-10342 in Patients With Advanced Solid Tumor
NCT04060511 ·Status: COMPLETED ·Phase: PHASE1
-
MAX-10181 Given Orally to Patients With Advanced Solid Tumor
NCT04122339 ·Status: UNKNOWN ·Phase: PHASE1
-
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
NCT03306420 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
NCT00794781 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
NCT02990481 ·Status: COMPLETED ·Phase: PHASE1